Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Shire steers Vyvanse toward binge eating as earnings come up aces

Shire CEO Flemming Ornskov has introduced a host of changes at the Ireland-based drugmaker since taking up the reins almost a year ago--and so far, they seem to be paying off. On Thursday, the company announced fourth-quarter earnings that handily beat market forecasts and predicted that growth will build in the year to come.

Questcor hires new CFO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Matthias Zachert leaves Merck KGaA and the stock drops

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide

Merck KGaA CFO  Matthias Zachert, who helped engineer a cost-cutting drive, is leaving for the top job at his former employer. News of his departure triggered a stock slide of more than 12%.

Former investment banker tapped as new Shire chairwoman

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Shire taps ex-investment banker Susan Kilsby to chair its board

There's movement at the top of Shire. With CEO Flemming Ornskov about a year into his job, the specialty drugmaker has tapped Susan Kilsby to be its new chairman. She will replace Matthew Emmens, Shire's former CEO and chairman since 2008, who is retiring.

Under investor pressure, Teva chairman pledges a smaller, more experienced board

It looks as if Teva Pharmaceutical Industries is taking its shareholders' concerns to heart. Just a few weeks after activist investor Benny Landa rallied support for a boardroom overhaul, Teva has promised to effect some changes: namely, cutting down the size of the board while upping the experience level.

Vivus commercial chief takes a hike after slew of exec exits

Since bungling the launch of obesity drug Qsymia, Vivus has lost more than half its board, its CFO, two CEOs and 20 staffers. Now, the company's chief commercial officer is following his departed colleagues out the door.

Novartis oncology chief Hoppenot exits to helm Incyte

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...